Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bruker Expands Capabilities of MALDI Biotyper Platform for Microbiology

Published: Tuesday, April 30, 2013
Last Updated: Tuesday, April 30, 2013
Bookmark and Share
Bruker launches library update for mycobacteria, showcases workflow optimization tools like MALDI Biotyper Pilot™, MALDI Biotyper Galaxy™ and novel MSBL software for MALDI-based functional resistance testing.

At the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Bruker shows new capabilities of the MALDI Biotyper™ platform.

The MALDI Biotyper (MBT) is the market-leading system for microbial identification based on MALDI-TOF mass spectrometry. It is widely used in clinical microbiology, industrial microbiology, animal health and food safety and has become the broadly accepted laboratory standard for next generation microbial identification.

While conventional biochemical testing takes time-consuming incubation after selection of the microbes from the culture plate, the MALDI Biotyper allows for an instantaneous identification of colonies from a plate.

The MALDI Biotyper system covers a broad range of more than 4,600 microbial isolates from gram-negative bacteria, gram-positive bacteria, yeasts, multicellular fungi and mycobacteria. It is broadly applicable as a standard identification tool in various fields of microbiology.

Microbial identification with the MALDI Biotyper is done using a proteomic fingerprint. This unique species-specific pattern is automatically compared with reference spectra in the MALDI Biotyper library.

In addition, the MALDI Biotyper supports the Open Microbiology Concept which allows customers to generate their own database entries from regional isolates via a push-button storage in a customer-specific sub-library.

The new second edition of the MBT Mycobacteria Library adds another 140 isolates from 37 new species. The library is fully compatible with all standard cultivation media for mycobacteria, such as solid Löwenstein-Jensen medium or in liquid culture using the MGIT™ system from Becton Dickinson.

With these added capabilities the MALDI Biotyper covers now more than 130 species of mycobacteria.

The new MALDI Biotyper Pilot™ accessory complements the satellite software to a complete, barcoded and paperless workflow. The MBT Pilot is used for light-guided manual target preparation using cross hairs to indicate the next position for preparation on the MALDI target.

Barcoding of the MALDI target and the sample, along with multiple isolate support, ensure that the complete process is fully traceable.

The new MALDI Biotyper Galaxy™ performs a quality-controlled automated deposition of the MALDI matrix onto the target plate. After the preparation it scans the target positions and checks if each spot is optimally prepared for MALDI Biotyper measurements.

The MBT Galaxy has a seamless integration into the MBT server coupled with on-board barcode reading and automated loading of the associated project work list. Both MBT Pilot and MBT Galaxy are scheduled to be commercially available in 2013.

The revolutionary MALDI-Biotyper-Spectrum-Beta-Lactamase™ workflow (MSBL™) enables users to perform patented functional beta-lactam antibiotic resistance testing for selected antibiotics on the MALDI Biotyper platform.

The cleavage of beta-lactam antibiotics, like penicillins, 3rd generation cephalosporins or carbapenems by resistant bacteria leads to specific mass shifts of the cleaved products.

Such mass shifts can be observed and monitored using the MALDI Biotyper, and automatically interpreted with the MSBL software module, which is also expected to be commercially availability later this year.

Dr. Wolfgang Pusch, Executive Vice President - Microbiology Business at Bruker Daltonics, explained: "At the 2013 ECCMID in Berlin, Bruker is again showcasing very significant developments to further improve and streamline the established MALDI Biotyper workflow. The MALDI Biotyper Pilot and MALDI Biotyper Galaxy automation accessories add further functionality for quality control and traceability and at the same time reduce the manual workload of the operators. The MSBL method is another major step ahead to apply the MALDI Biotyper platform also in the fields of hospital hygiene and epidemiology to get fast results concerning resistance of bacteria to selected antibiotics."

Professor David Livermore, University of East Anglia, Norwich, UK, commented: "I am very excited about the potential to detect beta-lactamases - and maybe other resistances - as well as to identify microbes by MALDI-TOF mass spectrometry. Early information about resistance is very important to antibiotic stewardship."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PREMIER Biosoft Announces Reseller Agreement with Bruker
Agreement aims to advance lipidomics and metabolomics research.
Monday, November 17, 2014
Bruker Sells GC Business
Bruker completed the divestiture of its GC and GC single-quadrupole (GC-SQ) mass spectrometry products to Techcomp Europe Ltd on October 31st.
Tuesday, November 04, 2014
Using LC-MS to Analyse Sulfonamides in Food Grade Honey
Sulfonamides are one of a number of groups of chemicals whose presence in honey is limited by international regulations.
Tuesday, July 22, 2014
Bruker MALDI Biotyper™ Receives CFDA Clearance
Company receives clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.
Thursday, June 26, 2014
Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker Granted FDA Clearance to Market the MALDI Biotyper CA System
Bruker able to market MALDI Biotyper CA System in the US for the identification of Gram negative bacterial colonies cultured from human specimens.
Tuesday, November 26, 2013
Bruker and SISCAPA Assay Technologies Announce Second-Phase Collaboration Agreement
The ongoing collaboration aims to exploit MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.
Monday, September 16, 2013
Bruker and ImaBiotech Announces Collaboration
Bruker to distribute ImaBiotech's Quantinetix software for quantitative MALDI imaging.
Friday, June 21, 2013
Bruker and 3M Sign Exclusive Patent License Agreement
The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin.
Tuesday, June 04, 2013
Bruker and SCiLS GmbH Announce an Exclusive Partnership
SCiLS Lab is the software developed by SCiLS GmbH which allows the user-friendly statistical analysis of large MALDI imaging datasets.
Wednesday, May 15, 2013
Biodesix Announces Agreement with Bruker Daltonics
The collaborative agreement sees Bruker Daltonics support Biodesix’ VeriStrat diagnostic test as well as future diagnostic tests based on MALDI-TOF mass spectrometry.
Wednesday, April 24, 2013
Bruker and the Genome British Columbia Proteomics Centre to Collaborate
The collaborative effort covers the development and validation of high-throughput assays for determining hemoglobin variants and diabetes risk.
Thursday, April 18, 2013
Bruker and Erasmus Medical Center Sign an Exclusive Licensing Agreement
Agreement for adding rapid beta-lactamase testing capabilities to the MALDI Biotyper system.
Friday, January 04, 2013
Bruker Announces New UK Centre of Excellence
Company introduces its integrated, state-of-the-art demonstration, applications and customer collaboration facilities.
Wednesday, October 03, 2012
Bruker and JMI Laboratories Announce Collaboration for Mass Spectrometry
The collaboration sees Bruker and JMI Laboratories partner in the field of fungal identification by proteomics fingerprinting.
Wednesday, June 20, 2012
Scientific News
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Flowing Electrons Help Ocean Microbes Gulp Methane
Recent work at Caltech has shown that microbes work together to consume large amounts of methane released from vents on the ocean floor by using electrons to share energy over long distances.
Thousands of Protein Interactions Identified
Thanks to the work by Utrecht University researcher Fan Liu and her colleagues, it is now possible to map the interactions between proteins in human cells.
Newly Identified Biochemical Pathway Could Be Target for Insulin Control
Researchers at Duke Medicine and the University of Alberta are reporting the identification of a new biochemical pathway to control insulin secretion from islet beta cells in the pancreas, establishing a potential target for insulin control.
Dirty,Crusty Meals Fit for (Long-Dormant) Microbes
Researchers apply the latest analytical techniques to further our understanding of desert biocrusts.
CSI -- On The Metabolite's Trail
Bioinformaticians at the University of Jena make the most efficient search engine for molecular structures available online.
First Complete Structural Study Of A Pegylated Protein
Significant data obtained at NUI Galway reports first crystal structure of a protein modified with a single PEG chain.
Potential Ovarian Cancer Biomarker Isolated
Researchers from North Carolina State University utilized a highly sensitive mass spectrometry analysis to identify and measure difficult-to-detect N-glycan biomarkers associated with ovarian cancers in stages I – IV.
Waters’ Centers of Innovation Program Honors Ohio State University Laboratory
Wysocki-led facility recognized for proteomics, disease research and mass spectrometry excellence.
Protein Aggregation After Heat Shock Is An Organized, Reversible Response
New study finds protein aggregation after heat exposure is a reversible cellular process, not unrecoverable damage from misfolding.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos